ArticleSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer.
Article in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- AHNAK2 is a novel diagnostic biomarker for gallbladder adenocarcinoma.Histology and histopathology · 2026Article
- Molecular convergence in gallbladder cancer: MEK-ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks.Cancer cell international · 2026Review
- Clinical and Molecular Signatures of Gallbladder Lesions: Insights into Metabolic and Inflammatory Pathways.Diagnostics (Basel, Switzerland) · 2026Article
- Exploring the efficacy of XAV939 and LF3 in targeting β-catenin signalling in gallbladder cancer cell lines.Discover oncology · 2026Article
- Utility of IMP3, p53, and S100P immunohistochemical stains in distinguishing reactive atypia from dysplasia in cholecystectomy specimens.Diagnostic pathology · 2024Article
- Gallbladder cancer: Progress in the Indian subcontinent.World journal of clinical oncology · 2024Review
- Review
- Next generation sequencing uncovers multiple miRNAs associated molecular targets in gallbladder cancer patients.Scientific reports · 2023Article
- Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer.World journal of gastrointestinal surgery · 2022Article
- Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway.Translational oncology · 2022Article
- Overview of current targeted therapy in gallbladder cancer.Signal transduction and targeted therapy · 2020Review
- Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.Biological research · 2020Article
- Serum Expression ofDisease markers · 2019Article
- Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.World journal of gastroenterology · 2017Review
- Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.Pathology oncology research : POR · 2017Article
- Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks.Cell death discovery · 2017Review
- CIZ1 promoted the growth and migration of gallbladder cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Gall bladder carcinoma: Aggressive malignancy with protean loco-regional and distant spread.World journal of clinical cases · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe inactivation of the tumor suppressor gene and activation of the proto-oncogene are key steps in the development of human cancer. p53 and beta-catenin are examples of such genes, respectively. In the present study, our aim was to determine the role of these genes in the carcinogenesis of the gallbladder by immunohistochemistry. PATIENTS AND
methodsSections from paraffin-embedded blocks of surgically resected specimens of gallbladder cancer (GBC) (80 cases), chronic cholecystitis (60 cases), and control gallbladders (10 cases) were stained with the monoclonal antibody p53, and polyclonal antibody beta-catenin. Results were scored semiquantitatively and statistical analysis performed. p53 expression was scored as percentage of the nuclei stained. Beta-catenin expression was scored as type of expression-membranous, cytoplasmic, and nuclear staining. Beta-catenin expression was correlated with tumor invasiveness, differentiation, and stage.
resultsOver-expression of p53 was seen in 56.25% of GBC cases and was not seen in chronic cholecystitis or in control gallbladders. p53 expression in gallbladder cancer was significantly higher than in inflammatory or control gallbladders (P < 0.0001). p53 expression increased with increasing tumor grade (P = 0.039). Beta-catenin nuclear expression was seen in 75% cases of gallbladder cancer and in no case of chronic cholecystitis and control gallbladder. Beta-catenin nuclear expression increased with tumor depth invasiveness, and grade (P = 0.028 and P = 0.0152, respectively).
conclusionp53 and beta-catenin nuclear expression is significantly higher in GBC. p53 expression correlates with increasing tumor grade while beta-catenin nuclear expression correlates with tumor grade and depth of invasion, thus suggesting a role for these genes in tumor progression of GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.